EE196 Cost-Effectiveness Analysis of Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer With Deficient Mismatch Repair (dMMR) and High Microsatellite Instability (MSI-H) in France
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.580
https://www.valueinhealthjournal.com/article/S1098-3015(25)03137-7/fulltext
Title :
EE196 Cost-Effectiveness Analysis of Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer With Deficient Mismatch Repair (dMMR) and High Microsatellite Instability (MSI-H) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03137-7&doi=10.1016/j.jval.2025.09.580
First page :
Section Title :
Open access? :
No
Section Order :
10174